Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 2
2008 5
2009 10
2010 3
2011 8
2012 8
2013 7
2014 11
2015 10
2016 8
2017 9
2018 6
2019 4
2020 5
2021 15
2022 6
2023 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 36974827

101 results

Results by year

Filters applied: . Clear all
Page 1
Degarelix for treating advanced hormone-sensitive prostate cancer.
Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blümle A, Schmucker C, Mayer B, Kunath F. Zengerling F, et al. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2. Cochrane Database Syst Rev. 2021. PMID: 34350976 Free PMC article. Review.
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP, Saltzstein DR, Sylvester JE, Karsh L, Mehlhaff BA, Pieczonka C, Bailen JL, Shi H, Ye Z, Faessel HM, Lin H, Zhu Y, Saad F, MacLean DB, Shore ND. Dearnaley DP, et al. Eur Urol. 2020 Aug;78(2):184-192. doi: 10.1016/j.eururo.2020.03.001. Epub 2020 Apr 6. Eur Urol. 2020. PMID: 32273183 Free article. Clinical Trial.
The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
Sari Motlagh R, Abufaraj M, Mori K, Aydh A, Rajwa P, Katayama S, Grossmann NC, Laukhtina E, Mostafai H, Pradere B, Quhal F, Karakiewicz PI, Enikeev DV, Shariat SF. Sari Motlagh R, et al. Eur Urol Oncol. 2022 Apr;5(2):138-145. doi: 10.1016/j.euo.2021.07.002. Epub 2021 Jul 21. Eur Urol Oncol. 2022. PMID: 34301529 Free article. Review.
101 results